Jun 7, 2022 09:45 PM
(This post was last modified: Jun 7, 2022 09:48 PM by Magical Realist.)
https://www.insider.com/rectal-cancer-dr...SVeLnWmexo
"An experimental drug appeared to clear every patient of rectal cancer with minimal side effects in an unprecedented study, but oncologists say it's too early to be sure that they're cured.
The drug, called dostarlimab, was given to 12 people with a specific type of rectal cancer every three weeks for six months in a small study at the Memorial Sloan Kettering Cancer Center in New York.
After the course of treatment, cancer was undetectable on physical exam, endoscopy, PET, and MRI scans for every person, the researchers from MSKCC said in a presentation at the annual meeting of the American Society of Clinical Oncology on Sunday
The participants didn't need any other treatment for up to a year, on average, and there were no side effects bad enough to impact day-to-day activities, the researchers said.
Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, San Francisco, who was not involved with the study, told the New York Times that complete remission in every single patient was "unheard-of".
Dr. Andrea Cercek, an oncologist at MSKCC and a study co-author, said there were "a lot of happy tears" from the trial participants when they found out no further treatment was necessary, per the Times.
Standard treatment involves a grueling combination of surgery, multiple chemotherapy drugs, and radiation to destroy cancer cells, often with nasty, permanent side effects such as nerve problems, infertility, and bowel and sexual dysfunction.
Cercek said in a press release that the implications of standard cancer treatment on people's quality of life were "substantial, especially in those where standard treatment would impact childbearing potential."
"As the incidence of rectal cancer is rising in young adults, this approach can have a major impact," Cercek said of dostarlimab's potential.
The cases of colorectal cancer among younger adults are projected to double by 2030, the MSKCC has said.
Dostarlimab works by helping the immune system identify and destroy cancer cells. The drug, which is branded as Jemperli, is already used for patients with endometrial cancer, but it wasn't clear if it would work for rectal malignancies. The participants in the trial had a type of rectal cancer called "mismatch repair deficiency". About 5 to 10% of people with rectal cancer have this type of cancer, where the genes responsible for correcting any mistakes during cell replication are faulty. The study can't tell us if dostarlimab will work in patients with other types of rectal cancer..."
"An experimental drug appeared to clear every patient of rectal cancer with minimal side effects in an unprecedented study, but oncologists say it's too early to be sure that they're cured.
The drug, called dostarlimab, was given to 12 people with a specific type of rectal cancer every three weeks for six months in a small study at the Memorial Sloan Kettering Cancer Center in New York.
After the course of treatment, cancer was undetectable on physical exam, endoscopy, PET, and MRI scans for every person, the researchers from MSKCC said in a presentation at the annual meeting of the American Society of Clinical Oncology on Sunday
The participants didn't need any other treatment for up to a year, on average, and there were no side effects bad enough to impact day-to-day activities, the researchers said.
Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, San Francisco, who was not involved with the study, told the New York Times that complete remission in every single patient was "unheard-of".
Dr. Andrea Cercek, an oncologist at MSKCC and a study co-author, said there were "a lot of happy tears" from the trial participants when they found out no further treatment was necessary, per the Times.
Standard treatment involves a grueling combination of surgery, multiple chemotherapy drugs, and radiation to destroy cancer cells, often with nasty, permanent side effects such as nerve problems, infertility, and bowel and sexual dysfunction.
Cercek said in a press release that the implications of standard cancer treatment on people's quality of life were "substantial, especially in those where standard treatment would impact childbearing potential."
"As the incidence of rectal cancer is rising in young adults, this approach can have a major impact," Cercek said of dostarlimab's potential.
The cases of colorectal cancer among younger adults are projected to double by 2030, the MSKCC has said.
Dostarlimab works by helping the immune system identify and destroy cancer cells. The drug, which is branded as Jemperli, is already used for patients with endometrial cancer, but it wasn't clear if it would work for rectal malignancies. The participants in the trial had a type of rectal cancer called "mismatch repair deficiency". About 5 to 10% of people with rectal cancer have this type of cancer, where the genes responsible for correcting any mistakes during cell replication are faulty. The study can't tell us if dostarlimab will work in patients with other types of rectal cancer..."
